Debra is responsible for Veramed's Biometrics FSP offering in North America. She excels in building and maintaining strong relationships and developing high performing teams.

Debra is a highly skilled leader with over 24 years of experience in clinical research. She started her career as a Statistical Programmer, and subsequently advanced to managerial positions, building and overseeing global teams and developing leadership strategies. In her most recent role as Senior Director of Data Management at a global CRO, Debra provided strategic guidance and operational oversight for a large team of clinical data science professionals.

Debra holds a Bachelor of Arts Degree in Statistics and German from the University of Minnesota, a Master of Business Administration from the University of Saint Thomas and a Certificate in International Business Management from National University of Ireland's Michael Smurfit Graduate Business School.

With more than 25 years in the Biopharma industry with Clinical Research Organizations, leading global teams across Standards & Innovation, Data Management, Statistics, Statistical Programming and Medical Writing, Karen Curran holds the position of Chief Strategic Officer at Veramed.

A proven track record in successfully developing, managing and growing dynamic business units and specific market expertise in providing strategic guidance and developing innovative solutions for biometric processes across a broad range of pharma and CRO environments means Karen can offer valuable expertise and insights to any project. She has extensive CDISC management knowledge and submission experience, including the FDA, EMEA and PMDA, and sits on the CDISC Board of Directors. She has also been involved in the PHUSE organisation for more than 5 years.

Prior to joining Veramed, Karen held roles as Vice President for Global Strategic Partnerships at IQVIA, Vice President and General Manager at CSG, and Vice President of Global Strategic Partnerships at Covance. She obtained her BS in Mathematics from Shippensburg University, and her MBA from Penn State University.

Having a statistical career spanning all phases of drug development through supporting regulatory submissions, post-submission registries and observational studies, Katherine brings more than 35 years of experience within the pharmaceutical industry to the Veramed team. This is backed by an additional 20+ years in the service sector, where she developed extensive knowledge of operational and client account management, supporting and developing staff in their careers while always keeping client needs at the forefront of decisions.

Katherine achieved a BSc in Mathemetics from Leeds University, followed by an MSc in Applied Statistics from Sheffield Hallam University. An active member of Statisticians in the Pharmaceutical Industry (PSI), she has held positions on their Board of Directors, including a stint as Chair from 2011 to 2012.

Terri is the Vice President of Biometrics at Veramed, with over 20 years of experience with operating and managing data management and biostatistical teams. Terri has overall responsibility for senior management oversight of the data management and biostatistical services and deliverables at Veramed. She works closely with her team to ensure that all deliverables are being performed in accordance with quality standards and that each client is receiving excellent service to advance their trials. She is adept at understanding each client’s unique requirements and helps customize efficient data solutions that adhere to quality standards. Prior to Veramed, Terri was Principal Consultant and Founder of a Biometrics CRO for over 18 years.

Terri holds a Master’s in Public Health (MPH), Epidemiology and Biostatistics from Boston University School of Public Health and a B.A, Biology from St. Anselm College.

James is an expert Statistical Programmer and Director within the Pharmaceutical space. He has led multiple projects, teams and studies over a wide range of therapeutic areas. James’ ability to innovate and continually develop throughout his career has ensured he has a diverse range of skills spanning team leadership, account management, governance, and technical implementation. James has remained an active programmer throughout and has a keen interest in process improvement. This has led to the development and implementation of various technical solutions and speed-enhancing initiatives such as STDM automation.
He has held previous leadership positions within biometrics, as well as numerous contract positions within statistical programming.

With over 25 years of experience in statistical programming, Mark is an expert in integrated analysis and submissions. He leads a global department, bringing his deep expertise in recruitment, business development, and client relations, while maintaining a strong focus on operational and programming support. Mark's hands-on approach ensures the successful delivery of integrated analysis solutions, driving process improvements and supporting system deployment and maintenance. His comprehensive experience enables him to oversee complex analysis workflows and ensure timely, accurate submissions, contributing to the seamless execution of clinical trial projects.

Zainab is the head of Veramed's Data Monitoring Committee Business Unit, which provides high quality data analysis centre services to support DMC meetings. She has over 20 years experience as a statistician within the pharmaceutical industry having worked across Phase I-IV and numerous therapeutic areas. Zainab has extensive experience providing statistical support to DMCs as an unblinded statistician and has also served as the expert statistician on DMCs. She has taken the lead on developing and updating SOPs and training to support Veramed's DMC services, including the introduction of specialised training for teams working on DMC projects and hands-on mentoring and workshops for statisticians who perform the independent unblinded statistician role for DMC projects. Zainab has played an instrumental role in growing the DMC business unit, such that Veramed is now a DMC services preferred provider for a number of Top 20 pharmaceutical clients.

Adam is a seasoned professional with over 25 years of experience in the pharmaceutical and healthcare industries. His expertise lies in unlocking the true value of data and analysis across various business areas, with a particular focus on Real-World Evidence (RWE) generation since 2013. Adam oversaw the delivery of multiple client engagements to unlock value from anonymised patient data.

Adam's expertise in data analysis, RWE generation, and strategic communication makes him a valuable asset in driving innovation and informed decision-making in the healthcare and pharmaceutical sectors.

Adam has held a variety of leadership positions at IQVIA, including Vice President of Real-World Evidence (RWE) for the NEMEA region, where he played a pivotal role in driving the company's RWE portfolio to new heights.

Lixin Gao is the founder and President of BioPier Inc., which was acquired by Veramed in 2024. He continues to lead BioPier, LLC, a Veramed U.S. subsidiary, where he manages daily operations with a strong focus on integrated analysis and regulatory submissions. A skilled hands-on leader in the field of biometrics, Lixin is known for his ability to deliver high-quality, timely, and efficient solutions, specializing in fast-track study analysis and regulatory approvals.